Analyses / RGTI
Early-stage quantum computing hardware vendor; cash-rich but unprofitable; high volatility and insider selling pressure.
A free account reveals RGTI's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.
The Thesis
▲ Bull Case
Quantum computing TAM expanding; CHIPS Act funding may accelerate adoption; current cash position ($17.25 current ratio) funds runway; potential for 2-3x if commercialization inflects or strategic partnership materializes.
▼ Bear Case
Revenue declining (-18.5% YoY); net margin at -3050%, operating margin -1194%; massive cash burn; P/S of 717x indicates extreme early-stage valuation risk; insider selling 1.85x buys; 73% drawdown from 52-week high suggests momentum collapse; competitive pressure from IonQ, D-Wave.
Valuation
OVERVALUED (on traditional metrics) / UNVALUED (on fundamentals) — score 25/100
RGTI trades on speculative TAM and CHIPS Act tailwinds, not current profitability. P/S 717x, P/B 29.1x are extreme for any operating company. No meaningful earnings power yet. Valuation hinges entirely on quantum commercialization path and capital-raise ability.
Technical Levels
Support · $12.53 (52-week low; cash/carry floor) · $14.00 (Recent intraday support) · $15.15 (Today's intraday low)
Resistance · $15.94 (Today's intraday high) · $17.50 (200-day MA (approx)) · $20.00 (Psychological / pre-earnings level) · $58.15 (52-week high; massive resistance)
Financial Health
Score 60/100. Rigetti has ample liquidity (current & quick ratios >16), implying strong cash position relative to current liabilities. However, massive operating losses mean capital burn is the material risk, not insolvency in next 12 months. If revenue does not materially improve or capital raise needed, dilution will pressure stock. Debt-to-equity data unavailable.
Catalysts
| CHIPS Act funding awards / partnership announcements | Next 6–12 months | high |
| Major customer announcement or trial deployment | 12–18 months | high |
| Capital raise (equity or debt) | Possible 12–24 months if cash burn accelerates | high (likely dilutive) |
| Quarterly earnings misses or guidance cuts | Any quarter | medium (high volatility stock may rally/dump on sentiment swings) |
| M&A / strategic acquisition by larger semiconductor or defense player | Speculative; 1–3 years | very high (binary outcome) |
Risk Flags
See RGTI's full trade plan — free
Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.
Unlock RGTI free →Recent News
- Rising Losses Weigh on Rigetti's Outlook: Sell or Hold RGTI Stock Now?Yahoo
- Quantum Stocks Fall as Rate-Hike Odds Climb: IonQ Sinks 4%, Rigetti and D-Wave Pull BackYahoo
- Takeaways From IonQ's Investor Day: A New Quantum System and $1.8 Billion DealYahoo
- Top 5 Stocks Poised to Profit From the CHIPS Quantum Incentive WaveYahoo
- The Next Winners May Not Be the Stocks You ExpectYahoo
You've read your 2 free analyses
Create a free account for unlimited analyses — every name on the page, plus live tools on 5,000+ tickers. No card required.
Read the full RGTI analysis — free →Free to read · 2 analyses every 30 days without an account
More Analyses
RGTI FAQ
Is RGTI a buy right now?
Rigetti Computing Inc's current read is a speculative setup with 35 confidence over a 6-12 months horizon. Valuation: OVERVALUED (on traditional metrics) / UNVALUED (on fundamentals). See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.
Is RGTI overvalued?
OVERVALUED (on traditional metrics) / UNVALUED (on fundamentals) (valuation score 25/100). RGTI trades on speculative TAM and CHIPS Act tailwinds, not current profitability. P/S 717x, P/B 29.1x are extreme for any operating company. No meaningful earnings power yet. Valuation hinges entirely on quantum commercialization path and capital-raise ability.
What are the risks of buying RGTI?
Revenue declining (-18.5% YoY); net margin at -3050%, operating margin -1194%; massive cash burn; P/S of 717x indicates extreme early-stage valuation risk; insider selling 1.85x buys; 73% drawdown from 52-week high suggests momentum collapse; competitive pressure from IonQ, D-Wave.